Can a new triple therapy outsmart resistant myeloma?
NCT ID NCT07772024
First seen Aug 19, 2026 · Last updated Aug 19, 2026
Summary
This phase 3 trial is testing whether adding an experimental drug called inobrodib to a standard two-drug regimen (pomalidomide and dexamethasone) can help people whose multiple myeloma has come back or stopped responding to prior treatments. Participants will be randomly assigned to receive either the new triple combination or one of several standard treatment options chosen by their doctor. The study will measure how long people live without their cancer worsening and how many achieve a meaningful response, along with overall survival and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inobrodib combined with pomalidomide and dexamethasone
- What this could lead to
- If successful, this combination could offer a new treatment option that delays disease progression and improves response rates for people with relapsed or refractory multiple myeloma.
- What could go wrong
- This is an early-phase comparison, and the combination may not prove more effective than existing therapies. Side effects could be more severe or less tolerable than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Regis Clinical Research
RECRUITINGMiami, Florida, 33126, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tropical tea shrink blood cancers?
- Can a new immune cell therapy outsmart resistant blood cancers?
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a single gene therapy turn the body into a Cancer-Fighting factory?
- Engineered immune cells take on incurable blood cancer
- New CAR T-Cell therapy targets Hard-to-Treat myeloma